Nitazoxanide

From Wikipedia, the free encyclopedia

Nitazoxanide
Systematic (IUPAC) name
[2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate
Identifiers
CAS number 55981-09-4
ATC code P01AX11
PubChem 41684
DrugBank APRD00558
Chemical data
Formula C12H9N3O5S 
Mol. mass 307.283 g/mol
Pharmacokinetic data
Bioavailability  ?
Protein binding 99%
Metabolism Hydrolyzed to tizoxanide
Half life  ?
Excretion Renal, biliary and fecal
Therapeutic considerations
Pregnancy cat.

B(US)
Legal status

℞-only(US)
Routes Oral (tablets and suspension)

Nitazoxanide, also known by the brand names Alinia and Annita, is a synthetic nitrothiazolyl-salicylamide derivative and an antiprotozoal agent. It is approved for the treatment of infectious diarrhea caused by Cryptosporidium parvum and Giardia lamblia in patients 1 year of age and older.

Nitazoxanide is currently in Phase II clinical trials for the treatment of hepatitis C, in combination with peginterferon alfa-2a and ribavirin.[1][2]

Contents

[edit] Adverse effects

Side effects are mostly gastrointestinal, and include abdominal pain, vomiting and diarrhea.

[edit] Pharmacokinetics

Nitazoxanide is a prodrug. Following oral administration, it is rapidly hydrolyzed to its active metabolite, tizoxanide, which is 99% protein bound. Peak concentrations are observed 1–4 hours after administration. It is excreted in the urine, bile and feces.

[edit] References

[edit] Notes

  1. ^ Medical News Today (August 16, 2007). "Romark Initiates Clinical Trial Of Alinia For Chronic Hepatitis C In The United States". Press release. Retrieved on 2007-10-11.
  2. ^ Franciscus, Alan (October 2, 2007). Hepatitis C Treatments in Current Clinical Development. HCV Advocate. Retrieved on 2007-10-11.

[edit] Sources


v • d • e
Agents against amoebiasis and other protozoal diseases (P01A)
Hydroxyquinoline derivatives
Nitroimidazole derivatives
Other
Languages